Influenza Nucleoprotein Delivered with Aluminium Salts Protects Mice from an Influenza A Virus That Expresses an Altered Nucleoprotein Sequence

Overview

Journal PLoS One

Specialties General Medicine
Science

Date 2013 Apr 25

PMID 23613928

Citations 13

Authors

Megan K L MacLeod

Alexandria David

Niyun Jin

Laura Noges

Jieru Wang

John W Kappler

Philippa Marrack

Affiliations

Soon will be listed here.

Abstract

Influenza virus poses a difficult challenge for protective immunity. This virus is adept at altering its surface proteins, the proteins that are the targets of neutralizing antibody. Consequently, each year a new vaccine must be developed to combat the current recirculating strains. A universal influenza vaccine that primes specific memory cells that recognise conserved parts of the virus could prove to be effective against both annual influenza variants and newly emergent potentially pandemic strains. Such a vaccine will have to contain a safe and effective adjuvant that can be used in individuals of all ages. We examine protection from viral challenge in mice vaccinated with the nucleoprotein from the PR8 strain of influenza A, a protein that is highly conserved across viral subtypes. Vaccination with nucleoprotein delivered with a universally used and safe adjuvant, composed of insoluble aluminium salts, provides protection against viruses that either express the same or an altered version of nucleoprotein. This protection correlated with the presence of nucleoprotein specific CD8 T cells in the lungs of infected animals at early time points after infection. In contrast, immunization with NP delivered with alum and the detoxified LPS adjuvant, monophosphoryl lipid A, provided some protection to the homologous viral strain but no protection against infection by influenza expressing a variant nucleoprotein. Together, these data point towards a vaccine solution for all influenza A subtypes.

Citing Articles

Alterations in arthropod and neuronal exosomes reduce virus transmission and replication in recipient cells.

Fasae K, Neelakanta G, Sultana H Extracell Vesicles Circ Nucl Acids. 2023; 3(3):247-279.

PMID: 36939419 PMC: 10018778. DOI: 10.20517/evcna.2022.30.

Influenza Chimeric Protein (3M2e-3HA2-NP) Adjuvanted with PGA/Alum Confers Cross-Protection against Heterologous Influenza A Viruses.

Kwak C, Nguyen Q, Kim J, Kim T, Poo H J Microbiol Biotechnol. 2020; 31(2):304-316.

PMID: 33263336 PMC: 9705887. DOI: 10.4014/jmb.2011.11029.

Tolerance induction in memory CD4 T cells is partial and reversible.

Gray J, Al-Khabouri S, Morton F, Clambey E, Gapin L, Matsuda J Immunology. 2020; 162(1):68-83.

PMID: 32931017 PMC: 7730012. DOI: 10.1111/imm.13263.

Improving Cross-Protection against Influenza Virus Using Recombinant Vaccinia Vaccine Expressing NP and M2 Ectodomain Tandem Repeats.

Wang W, Huang B, Wang X, Tan W, Ruan L Virol Sin. 2019; 34(5):583-591.

PMID: 31240620 PMC: 6814692. DOI: 10.1007/s12250-019-00138-9.

Multifunctional cytokine production reveals functional superiority of memory CD4 T cells.

Westerhof L, McGuire K, MacLellan L, Flynn A, Gray J, Thomas M Eur J Immunol. 2019; 49(11):2019-2029.

PMID: 31177549 PMC: 6900100. DOI: 10.1002/eji.201848026.

References

Wang M, Lamberth K, Harndahl M, Roder G, Stryhn A, Larsen M . CTL epitopes for influenza A including the H5N1 bird flu; genome-, pathogen-, and HLA-wide screening. Vaccine. 2007; 25(15):2823-31. DOI: 10.1016/j.vaccine.2006.12.038. View

LaMere M, Lam H, Moquin A, Haynes L, Lund F, Randall T . Contributions of antinucleoprotein IgG to heterosubtypic immunity against influenza virus. J Immunol. 2011; 186(7):4331-9. PMC: 3159153. DOI: 10.4049/jimmunol.1003057. View

Poland G, Jacobson R, Targonski P . Avian and pandemic influenza: an overview. Vaccine. 2007; 25(16):3057-61. DOI: 10.1016/j.vaccine.2007.01.050. View

Hohn H, Neukirch C, Freitag K, Necker A, Hitzler W, Seliger B . Longitudinal analysis of the T-cell receptor (TCR)-VA and -VB repertoire in CD8+ T cells from individuals immunized with recombinant hepatitis B surface antigen. Clin Exp Immunol. 2002; 129(2):309-17. PMC: 1906443. DOI: 10.1046/j.1365-2249.2002.01841.x. View

McKee A, MacLeod M, Kappler J, Marrack P . Immune mechanisms of protection: can adjuvants rise to the challenge?. BMC Biol. 2010; 8:37. PMC: 2864095. DOI: 10.1186/1741-7007-8-37. View

Marrack P, McKee A, Munks M . Towards an understanding of the adjuvant action of aluminium. Nat Rev Immunol. 2009; 9(4):287-93. PMC: 3147301. DOI: 10.1038/nri2510. View

Grimm D, Staeheli P, Hufbauer M, Koerner I, Martinez-Sobrido L, Solorzano A . Replication fitness determines high virulence of influenza A virus in mice carrying functional Mx1 resistance gene. Proc Natl Acad Sci U S A. 2007; 104(16):6806-11. PMC: 1871866. DOI: 10.1073/pnas.0701849104. View

Tetsutani K, Ishii K . Adjuvants in influenza vaccines. Vaccine. 2012; 30(52):7658-61. DOI: 10.1016/j.vaccine.2012.10.007. View

McElhaney J, Xie D, Hager W, Barry M, Wang Y, Kleppinger A . T cell responses are better correlates of vaccine protection in the elderly. J Immunol. 2006; 176(10):6333-9. DOI: 10.4049/jimmunol.176.10.6333. View

10.

Belz G, Bedoui S, Kupresanin F, Carbone F, Heath W . Minimal activation of memory CD8+ T cell by tissue-derived dendritic cells favors the stimulation of naive CD8+ T cells. Nat Immunol. 2007; 8(10):1060-6. DOI: 10.1038/ni1505. View

11.

Endo A, Itamura S, Iinuma H, Funahashi S, Shida H, Koide F . Homotypic and heterotypic protection against influenza virus infection in mice by recombinant vaccinia virus expressing the haemagglutinin or nucleoprotein of influenza virus. J Gen Virol. 1991; 72 ( Pt 3):699-703. DOI: 10.1099/0022-1317-72-3-699. View

12.

Hikono H, Kohlmeier J, Ely K, Scott I, Roberts A, Blackman M . T-cell memory and recall responses to respiratory virus infections. Immunol Rev. 2006; 211:119-32. DOI: 10.1111/j.0105-2896.2006.00385.x. View

13.

de Wit E, Spronken M, Bestebroer T, Rimmelzwaan G, Osterhaus A, Fouchier R . Efficient generation and growth of influenza virus A/PR/8/34 from eight cDNA fragments. Virus Res. 2004; 103(1-2):155-61. DOI: 10.1016/j.virusres.2004.02.028. View

14.

Kees U, Krammer P . Most influenza A virus-specific memory cytotoxic T lymphocytes react with antigenic epitopes associated with internal virus determinants. J Exp Med. 1984; 159(2):365-77. PMC: 2187216. DOI: 10.1084/jem.159.2.365. View

15.

Heiny A, Miotto O, Srinivasan K, Khan A, Zhang G, Brusic V . Evolutionarily conserved protein sequences of influenza a viruses, avian and human, as vaccine targets. PLoS One. 2007; 2(11):e1190. PMC: 2065905. DOI: 10.1371/journal.pone.0001190. View

16.

Giannini S, Hanon E, Moris P, Van Mechelen M, Morel S, Dessy F . Enhanced humoral and memory B cellular immunity using HPV16/18 L1 VLP vaccine formulated with the MPL/aluminium salt combination (AS04) compared to aluminium salt only. Vaccine. 2006; 24(33-34):5937-49. DOI: 10.1016/j.vaccine.2006.06.005. View

17.

Zehn D, Turner M, Lefrancois L, Bevan M . Lack of original antigenic sin in recall CD8(+) T cell responses. J Immunol. 2010; 184(11):6320-6. PMC: 2982183. DOI: 10.4049/jimmunol.1000149. View

18.

Rahman F, Dahmen A, Herzog-Hauff S, Bocher W, Galle P, Lohr H . Cellular and humoral immune responses induced by intradermal or intramuscular vaccination with the major hepatitis B surface antigen. Hepatology. 2000; 31(2):521-7. DOI: 10.1002/hep.510310237. View

19.

Zhou B, Li Y, Halpin R, Hine E, Spiro D, Wentworth D . PB2 residue 158 is a pathogenic determinant of pandemic H1N1 and H5 influenza a viruses in mice. J Virol. 2010; 85(1):357-65. PMC: 3014153. DOI: 10.1128/JVI.01694-10. View

20.

Wilkinson T, Li C, Chui C, Huang A, Perkins M, Liebner J . Preexisting influenza-specific CD4+ T cells correlate with disease protection against influenza challenge in humans. Nat Med. 2012; 18(2):274-80. DOI: 10.1038/nm.2612. View